Route 92 Medical v. Q’Apel Medical: Five-Patent Neurovascular Suit Ends in Prejudicial Dismissal
Route 92 Medical filed suit in Delaware against Q’Apel Medical asserting five patents covering neurovascular access and aspiration technology, targeting Q’Apel’s Hippo-Cheetah system. After 210 days, the parties jointly stipulated to dismiss the action with prejudice — each side bearing its own costs.
Neurovascular access IP dispute ends at stipulated dismissal after 210 days
Route 92 Medical, Inc. filed this infringement action on 7 October 2024 in the District of Delaware before Judge Richard G. Andrews, asserting five US patents — US10456555B2, US10213582B2, US11871944B2, US11925770B2, and US10646239B2 — against Q’Apel Medical, Inc. The asserted patents relate to neurovascular access and aspiration catheter technology, and the accused product is Q’Apel’s Hippo-Cheetah system, a large-bore aspiration platform used in stroke intervention procedures.
The case closed on 5 May 2025 — just 210 days after filing — when the parties submitted a joint stipulation for dismissal. Judge Andrews entered an order dismissing the action with prejudice, with each side bearing its own costs and attorneys’ fees. Dismissal with prejudice is a final adjudication on the merits; Route 92 Medical is barred from reasserting the same claims against Q’Apel on the same patents in any future proceeding.
The 210-day resolution timeline is notably short for a five-patent Delaware district court case, where Markman hearings and claim construction alone frequently extend past that window. The speed of resolution and the absence of any cost award are consistent with a confidential settlement reached before substantial litigation milestones — though the public record does not confirm or disclose any settlement terms. Whether a licensing arrangement, cross-licence, or other commercial resolution underlies the stipulation is not publicly known.
Filing to Dismissed with Prejudice in 210 days
210 days — shorter than the median Delaware patent case, suggesting early resolution
Dismissed with prejudice: what the stipulated order means for both parties
Stipulated dismissal with prejudice bars all future reassertion
A dismissal with prejudice entered by stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) operates as a final judgment on the merits. Route 92 Medical cannot refile this specific infringement action against Q’Apel on any of the five asserted patents based on the same accused product. The res judicata effect is immediate and permanent, giving Q’Apel a durable shield against re-litigation of these claims.
Rule 41(a) — final on the meritsRoute 92 Medical surrenders future claim rights — likely for consideration
Agreeing to dismiss with prejudice is a significant concession for a patent plaintiff. Route 92 Medical loses the ability to enforce these five patents against Q’Apel’s Hippo-Cheetah system in any future suit. The mutual cost-bearing provision and the speed of resolution are consistent with a negotiated outcome in which Route 92 Medical received some form of commercial consideration — though no terms are disclosed in the public record.
No future suit on these patentsQ’Apel obtains permanent insulation from these five patent claims
Q’Apel Medical exits the litigation without any adverse finding and without a cost order against it. The with-prejudice dismissal means the Hippo-Cheetah system cannot be challenged again by Route 92 Medical under the same five patents. This outcome strengthens Q’Apel’s commercial position in the neurovascular aspiration market, though it does not affect the underlying patent validity — those patents remain in force against third parties.
Protected against re-litigationNeurovascular access IP landscape remains contested for non-parties
While Q’Apel has resolved its exposure, Route 92 Medical’s five patents remain active and enforceable against other competitors in the large-bore aspiration and neurovascular access space. Companies developing stroke intervention catheters or similar access systems should note that these patents were considered commercially significant enough to litigate — and that no invalidity or non-infringement finding was made, leaving the patents at full strength.
Patents active vs. third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Route 92 Medical, Inc. | Company | Neurovascular device company — holder of US10456555B2 and four related access system patentsSearch in Eureka ↗ |
| Defendant | Q’Apel Medical, Inc. | Company | Q’Apel Medical, Inc. — developer of the Hippo-Cheetah large-bore aspiration systemSearch in Eureka ↗ |
| Plaintiff counsel | Benjamin J. Everton | Attorney | Counsel for Route 92 Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Irfan A. Lateef | Attorney | Counsel for Route 92 Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John C. Phillips , Jr. | Attorney | Counsel for Route 92 Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan C. Haney | Attorney | Counsel for Route 92 Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rhett D. Ramsey | Attorney | Counsel for Route 92 Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stephen C. Jensen | Attorney | Counsel for Route 92 Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Route 92 Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew Dieter Cordo | Attorney | Counsel for Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Catherine R. Lacey | Attorney | Counsel for Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Frederick L. Cottrell , III | Attorney | Counsel for Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Jing Wang | Attorney | Counsel for Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Jordan R. Jaffe | Attorney | Counsel for Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant law firm | Richards, Layton & Finger, PA | Law Firm | Representing Q’Apel Medical, Inc.Search in Eureka ↗ |
| Defendant law firm | Wilson Sonsini Goodrich & Rosati, LLP | Law Firm | Representing Q’Apel Medical, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The order’s phrasing — ‘hereby dismisses this action with prejudice’ entered ‘[u]pon consideration of the parties’ Stipulation’ — reflects a court-endorsed consent order rather than any judicial finding on the merits. No claim construction, infringement analysis, or validity determination is embedded in the ruling. For both parties, the order’s legal effect is defined solely by the with-prejudice bar: Route 92 Medical’s claims are extinguished as to Q’Apel, while the asserted patents remain fully valid and enforceable against the broader market.
US10456555B2 and four related patents — neurovascular access and aspiration systems
The five asserted patents — US10456555B2, US10213582B2, US11871944B2, US11925770B2, and US10646239B2 — share application dates ranging from late 2017 through April 2023, indicating a sustained continuation prosecution strategy by Route 92 Medical. The patents collectively cover neurovascular access systems, including large-bore aspiration catheters and related methods used in endovascular stroke treatment. The technology domain sits at the intersection of interventional neurology and vascular access device engineering.
Large-bore aspiration technology is a commercially critical segment of the stroke intervention device market, where speed of clot removal is directly tied to patient outcomes. Route 92 Medical’s willingness to assert five patents simultaneously against a single competitor’s product — the Hippo-Cheetah system — suggests these claims are viewed as broadly covering platform-level architecture rather than narrow design features. For competitors in the aspiration-first stroke treatment space, the portfolio represents a meaningful freedom-to-operate risk that warrants proactive analysis.
Should you run an FTO against Route 92 Medical’s neurovascular access patents?
Any company developing, manufacturing, or commercialising large-bore aspiration catheters, neurovascular guide systems, or stroke intervention access devices should assess freedom to operate against Route 92 Medical’s five-patent portfolio. The patents span application dates from 2017 to 2023, meaning the family likely contains pending continuations not yet publicly visible. The Hippo-Cheetah litigation confirms Route 92 Medical is actively enforcing — not merely holding — this portfolio.
PatSnap Eureka’s FTO Search Agent can map the full continuation family from each of the five application numbers, identify claim scope overlaps with your product architecture, and flag pending sibling applications that may issue with broader or reoriented claims. For R&D teams in the neurovascular access space, running this analysis before design lock-in is materially cheaper than post-launch litigation exposure in Delaware.
Run a freedom-to-operate analysis on US10456555B2 to assess your product’s exposure
Run FTO in Eureka →Similar neurovascular device patent cases in Delaware District Court
Related infringement actions involving neurovascular access, aspiration catheter, and stroke intervention patents filed in the District of Delaware.
What this case signals for the neurovascular device IP landscape
A five-patent filing resolved in under seven months points to significant settlement leverage — and active enforcement posture — in the stroke intervention device sector.
Route 92 Medical’s portfolio signals aggressive enforcement in neuro access
Asserting five patents in a single action is a deliberate strategy to maximise settlement pressure and royalty leverage. Companies in the neurovascular aspiration catheter space — particularly those with large-bore or aspiration-first stroke systems — should audit their design freedom against Route 92 Medical’s portfolio before commercialising.
With-prejudice dismissal without costs is the hallmark of a structured resolution
When both parties agree to bear their own costs in a with-prejudice dismissal, it typically signals that value was exchanged outside the public record — commonly a licence, co-existence agreement, or commercial deal. IP teams tracking competitive dynamics should treat this outcome as a likely licensing event rather than a capitulation by either side.
Route v Q’Apel — key questions answered
Route 92 Medical sued Q’Apel Medical in Delaware District Court on 7 October 2024, asserting five patents covering neurovascular access and aspiration catheter technology against Q’Apel’s Hippo-Cheetah system. The case was dismissed with prejudice by joint stipulation on 5 May 2025, with each party bearing its own costs. No merits determination was made.
Route 92 Medical asserted five US patents: US10456555B2, US10213582B2, US11871944B2, US11925770B2, and US10646239B2. These patents relate to neurovascular access systems and large-bore aspiration catheter technology used in endovascular stroke intervention, with application dates spanning 2017 to 2023.
Dismissal with prejudice is a final adjudication that bars Route 92 Medical from refiling the same claims against Q’Apel Medical on the five asserted patents regarding the Hippo-Cheetah system. However, the patents remain valid and fully enforceable against all other third parties in the neurovascular device market.
The public record does not disclose any settlement terms. However, the combination of a with-prejudice dismissal, mutual cost-bearing, and a 210-day resolution timeline — before any Markman hearing — is consistent with a negotiated commercial resolution. Whether a licence, co-existence agreement, or other arrangement was reached is not confirmed in public filings.
Q’Apel Medical’s Hippo-Cheetah system is a large-bore aspiration platform designed for endovascular stroke treatment. Route 92 Medical alleged it infringes five patents covering neurovascular access catheter systems and methods. No infringement finding was made — the case resolved by stipulated dismissal before any substantive merits ruling.
PatSnap Eureka searches patents and litigation data to answer instantly.